EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Insulin Resistance Is a Modifying Factor for Parkinson's Disease

Alise Zagare, Ahmed Hemedan, Catarina Almeida, Daniela Frangenberg, Gemma Gomez-Giro, Paul Antony iD, Rashi Halder, Rejko Krüger, Enrico Glaab iD, Marek Ostaszewski, Giuseppe Arena, Jens C Schwamborn iD

Movement Disorders · 2025

DOI: 10.1002/mds.30039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2025. Verfasst von Alise Zagare und 11 weiteren Autor:innen. Beteiligte Einrichtung: Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. Hauptthemen laut MEDLINE: Parkinson Disease, Insulin Resistance. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds National de la Recherche Luxembourg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson's disease (PD) is the second most common, and the fastest‐growing neurodegenerative disorder with unclear etiology in most cases. Therefore, the identification of non‐genetic risk factors for PD pathology is crucial to develop effective preventative or therapeutic strategies. An increasing number of evidence suggests that central insulin resistance might have an essential role in PD pathology. Nevertheless, it is not clear whether insulin resistance arises from external factors/lifestyle, comorbidities such as type 2 diabetes or it can occur in a PD patient's brain independently from peripheral insulin resistance.

Objective

We aimed to investigate insulin resistance and its role in GBA1 mutation‐associated PD pathogenesis and phenotype severity.

Methods

Midbrain organoids, generated from induced pluripotent stem cells (iPSCs) of PD patients carrying the GBA1 ‐N370S heterozygous mutation (GBA‐PD) and healthy donors, were exposed to different insulin concentrations to modify insulin signaling function. Transcriptomics analysis was performed to explore insulin signaling gene expression patterns in GBA‐PD and to find a potential target for GBA‐PD‐associated phenotype rescue.

Results

The insulin signaling pathway genes show dysregulation in GBA‐PD. Particularly, we highlight that a knockdown of FOXO1 mitigates the loss of dopaminergic neurons and cellular death in GBA‐PD. Additionally, our findings suggest a promising therapeutic potential of the anti‐diabetic drug Pioglitazone in decreasing dopaminergic neuron loss associated with GBA‐PD.

Conclusion

Local insulin signaling dysfunction plays a substantial role in GBA‐PD pathogenesis, exacerbating dopaminergic neuron death. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseInsulin ResistanceHumansGlucosylceramidaseInduced Pluripotent Stem CellsMaleFemaleInsulinMutationMesencephalonDopaminergic NeuronsMiddle AgedForkhead Box Protein O1Signal TransductionAged

Stichwörter der Autor:innen

GBAParkinson's diseasecomorbititydiabetespioglitazone

Substanzen

GlucosylceramidaseInsulinGBA protein, humanForkhead Box Protein O1FOXO1 protein, human

Autor:innen und Institutionen

  • Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Bioinformatics Core Unit, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Health Sciences Research Center, Faculty of Health Sciences Research, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal.
  • Bioimaging Platform, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Sequencing Platform, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.

ORCID-Profile: Paul Antony, Enrico Glaab, Jens C Schwamborn

Förderung

  • Fonds National de la Recherche Luxembourg

Zitieren

APA

Zagare, A., Hemedan, A., Almeida, C., Frangenberg, D., Gomez-Giro, G., Antony, P., Halder, R., Krüger, R., Glaab, E., Ostaszewski, M., Arena, G., & Schwamborn, J. C. (2025). Insulin Resistance Is a Modifying Factor for Parkinson's Disease. Movement Disorders. https://doi.org/10.1002/mds.30039

Vancouver

Zagare A, Hemedan A, Almeida C, Frangenberg D, Gomez-Giro G, Antony P, et al. Insulin Resistance Is a Modifying Factor for Parkinson's Disease. Movement Disorders. 2025. doi:10.1002/mds.30039

BibTeX
@article{Zagare2025,
  author = {Zagare, Alise and Hemedan, Ahmed and Almeida, Catarina and Frangenberg, Daniela and Gomez-Giro, Gemma and Antony, Paul and Halder, Rashi and Krüger, Rejko and Glaab, Enrico and Ostaszewski, Marek and Arena, Giuseppe and Schwamborn, Jens C},
  title = {Insulin Resistance Is a Modifying Factor for Parkinson's Disease},
  journal = {Movement Disorders},
  year = {2025},
  doi = {10.1002/mds.30039}
}
Kostenlos starten →